期刊
JOURNAL OF INFECTIOUS DISEASES
卷 210, 期 3, 页码 435-440出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiu105
关键词
H7N9; Fludase (DAS181); oseltamivir; drug resistance; R292K; neuraminidase inhibitor
资金
- Influenza Division, Centers for Disease Control and Prevention
- Biomedical Advanced Research and Development Authority
- Centers for Disease Control and Prevention
Human infections caused by avian influenza A virus type subtype H7N9 have been associated with substantial morbidity and mortality. Emergence of virus variants carrying markers of decreased susceptibility to neuraminidase inhibitors was reported. Here we show that DAS181 (Fludase), an antiviral drug with sialidase activity, potently inhibited replication of wild-type influenza A(H7N9) and its oseltamivir-resistant R292K variants in mice. A once-daily administration initiated early after lethal infection hampered body weight loss and completely protected mice from lethality. We observed a time-dependent effect for 24-72-hour delayed DAS181 treatments on morbidity and mortality. The results warrant further investigation of DAS181 for influenza treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据